Evaluation of the anti-inflammatory effects of glycopyrronium added to indacaterol/mometasone on the allergen-induced late asthmatic response - Anti-inflammatory effects of Glycopyrronium

niversitair Medisch Centrum Groningen0 个研究点目标入组 28 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•1. Signed informed consent must be obtained prior to participation in the study.
•2. Male and female adult patients aged between 18 and 65 years old.
•3. Patients with a diagnosis of asthma for at least 6 months prior to Visit 1
•with current asthma severity of step 1-3 (GINA 2018).
•4. Patients with presence of allergy against house dust mite, cat or grass
•5. PC20 methacholine <= 8 mg/ml.
•6. Drop in FEV1 of 20% or more during the early asthmatic response and drop in
•FEV1 of 15% or more during the late asthmatic response, i.e. between 3-8 hours
•after allergen challenge.
•7. Patients able to produce sputum of sufficient quality for evaluation of cell
•differential counts 24 hours after the baseline allergen challenge at Visit 3.

•1. Patients who have a smoking history >= 10 pack-years (Note: 1 pack is
•equivalent to 20 cigarettes. 10 pack years = 1 pack/day x 10 years or *
•pack/day x 20 years). Ex-smokers are eligible for inclusion if they quit
•smoking for at least 6 months prior to Visit 1.
•2. Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).
•3. Patients with severe airway obstruction at baseline, FEV1 < 70% of predicted
•or < 1.5 liters.
•4. Patients who have had an asthma attack/exacerbation requiring systemic
•steroids or hospitalization or emergency room visit within 6 weeks of Visit 1.
•If patients experience an asthma attack/exacerbation requiring systemic
•steroids or hospitalization or emergency room visit, they may be re-screened 6
•weeks after recovery from the exacerbation.
•5. Patients who have had a respiratory tract infection or clinical significant
•asthma worsening as defined by Investigator within 4 weeks prior to Visit 1.
•Patients may be re-screened 4 weeks after recovery from their respiratory tract
•infection or asthma worsening.
•6. Patients who have ever required intubation for a severe asthma
•attack/exacerbation.
•7. Patients who have a clinical condition which is likely to be worsened by ICS
•administration (e.g. glaucoma, cataract and fragility fractures) who are
•according to investigator*s medical judgment at risk participating in the study.
•8. Patients treated with a LAMA for asthma within 3 months prior to Visit 1.

发起方